Aerie Pharmaceuticals
(NASDAQ) AERI
This security has been delisted. This page is retained for historical reference.
AERI News
Is Aerie Pharmaceuticals a Buy?
Is Aerie Pharmaceuticals a Buy?
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAERI Financials
Key Financial Metrics (TTM)
Gross Margin
86.17%
Operating Margin
-23.34%
Net Income Margin
-38.54%
Return on Equity
-2255.01%
Return on Capital
-18.62%
Return on Assets
-17.34%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$190.42M
Operating Income
-$23.24M
EBITDA
-$1.27M
Operating Cash Flow
$7.17M
Capital Expenditure
-$4.53M
Free Cash Flow
$2.64M
Cash & ST Invst.
$172.46M
Total Debt
$336.99M
Aerie Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonCurrently no data to display.
Quarterly Performance
Revenue
$36.13M
+23.3%
Gross Profit
$29.20M
+36.4%
Gross Margin
80.82%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
376
N/A
Net Income
-$26.83M
+32.4%
EBITDA
-$21.73M
+4.1%
Quarterly Fundamentals
Total Cash
$172.46M
+2.9%
Total Debt
$336.99M
+32.3%
Accounts Receivable
$73.88M
+14.4%
Inventory
$46.76M
+55.6%
Long Term Debt
$332.11M
+32.5%
Short Term Debt
$4.87M
+23.8%
Return on Assets
-17.34%
N/A
Return on Invested Capital
-14.79%
N/A
Free Cash Flow
-$12.21M
+39.0%
Operating Cash Flow
-$11.40M
+39.5%